Clinical Trial

Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety of the CAROL device for treating lung tumors in patients diagnosed with non-small cell lung cancer (NSCLC) with tumor size ≤ 2 cm (cT1b). The primary objective is to assess safety by monitoring and grading adverse events using the CTCAE v5.0 criteria at one month following the procedure.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-12; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Recruiting 2026-03-03
Trial Details
NCT Number NCT07122258
Lead Sponsor Tau Medical Australia Pty Ltd
Collaborators: Tau-MEDICAL Co., Ltd.
Conditions NSCLC (Non-small Cell Lung Cancer)
Enrollment 7 participants
Start Date 2026-03-01
Primary Completion 2027-03-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-05